Penumbra Gets FDA Clearance for Technology for Treating Strokes
By Kelly Cloonan
Penumbra received clearance from the Food and Drug Administration for a technology aimed at addressing acute ischemic stroke.
The medical-technology company said Thursday the clearance is for its Thunderbolt product, which uses advanced computer-assisted vacuum thrombectomy technology to detect, fatigue and completely ingest blood clots.
The technology is designed to minimize catheter manipulation and allow for safe, complete blood clot capture in order to restore blood flow to the brain and give patients a better chance at recovery, the company said.
"Thunderbolt marks the beginning of a new era in stroke management, one that we believe will fundamentally change outcomes for patients," said Shruthi Narayan, president of Penumbra.
Thunderbolt will be prepackaged with one of Penumbra's catheters, the company said.
Strokes are the second leading cause of death worldwide. Stroke mortality worldwide is projected to increase by 50% between 2020 to 2050, the company said, citing a recent analysis.
Shares were rising 3.3% after the bell.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
June 11, 2026 17:10 ET (21:10 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States